Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving signed informed consent.~2. Male and female patients ≥18 years of age~3. Body weight of \>40 kg~4. Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable.~5. Moderate-to-severe plaque-type psoriasis as defined by Psoriasis Activity and Severity Index (PASI) ≥12, body surface area (BSA) ≥10%, and Investigator Global Assessment (IGA) ≥3.~6. Candidate for systemic antipsoriatic treatment or phototherapy.~Exclusion Criteria:~1. Therapy-resistant psoriasis~2. Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit.~3. History of allergy or hypersensitivity to any component of the study treatment.~4. Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit.~5. Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orismilast modified release tablets 20 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Orismilast modified release tablets 30 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Orismilast modified release tablets 40 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Placebo tablets BID (Type: PLACEBO_COMPARATOR): Oral, twice daily morning and evening for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).